Active, recruiting, and completed cannabis clinical trials — curated from ClinicalTrials.gov with condition, phase, compound, and enrollment data. Updated monthly.
13
Recruiting
8
Active
5
Completed
4
Upcoming
30 trials found
Search ClinicalTrials.govNYU Langone Health
Double-blind, placebo-controlled RCT evaluating CBD (300mg/day) as adjunct therapy for PTSD in veterans who have not responded to first-line treatments. Primary endpoint is CAPS-5 score reduction at 12 weeks.
Memorial Sloan Kettering Cancer Center
Multicenter RCT evaluating nabiximols as opioid-sparing adjunct in cancer patients with moderate-to-severe pain. Assesses whether THC:CBD combination allows meaningful opioid dose reduction without compromising pain control.
UC San Diego School of Medicine
Double-blind RCT of pharmaceutical-grade CBD (10mg/kg/day) in children aged 5–18 with ASD and significant behavioral challenges. Evaluates effects on irritability, social communication, and repetitive behaviors.
King's College London / GW Research Ltd
Multicenter RCT of CBD (600mg/day) added to standard antipsychotic therapy in first-episode schizophrenia. Builds on the landmark McGuire et al. Phase 2 trial showing CBD improved positive symptoms and global functioning.
Jazz Pharmaceuticals
Long-term safety and tolerability extension study of nabiximols in MS patients with spasticity who completed prior Phase 3 trials. Evaluates 3-year safety profile, cognitive effects, and dependence potential.
University of Colorado Anschutz Medical Campus
Completed dose-finding RCT comparing CBD 150mg, 300mg, and 600mg vs. placebo for GAD over 8 weeks. Results submitted for publication. Preliminary data suggest 300mg as optimal dose with significant HAM-A score reductions.
Epygenix Therapeutics
Pediatric extension study of synthetic CBD (EPX-100) in Dravet syndrome patients aged 2–18. Evaluates long-term seizure control, safety, and quality of life in patients who completed the initial Phase 3 trial.
Harvard Medical School / Brigham and Women's Hospital
Pragmatic RCT comparing three cannabis formulations (high-CBD, balanced THC:CBD, high-THC) vs. placebo for chronic low back pain. Evaluates pain intensity, function, opioid use, and adverse effects over 12 weeks.
RespireRx Pharmaceuticals
Confirmatory Phase 3 RCT of dronabinol (2.5–10mg) for obstructive sleep apnea. Builds on Phase 2 data showing significant AHI reduction. Primary endpoint is apnea-hypopnea index reduction at 6 weeks.
Icahn School of Medicine at Mount Sinai
Double-blind RCT of CBD (400mg/day) for opioid use disorder in patients on buprenorphine maintenance. Evaluates cue-induced craving, anxiety, and relapse rates over 12 weeks, building on Hurd et al. heroin abstinence data.
University of São Paulo / FAPESP
Completed RCT of CBD (150–300mg/day) for psychosis in Parkinson's disease. Results published in JAMA Neurology showing significant improvement in BPRS psychosis subscale without worsening motor function or cognition.
Hannover Medical School
Multicenter RCT of THC (up to 10mg/day) for Tourette syndrome in adults. Evaluates tic severity (YGTSS), OCD symptoms, and quality of life over 12 weeks. Builds on two prior positive small RCTs.
University of Nottingham
Double-blind RCT of CBD (300mg/day) for mild-to-moderate ulcerative colitis. Evaluates clinical remission, mucosal healing (endoscopy), and inflammatory biomarkers (CRP, fecal calprotectin) over 10 weeks.
Mayo Clinic
Completed RCT of nabilone (1–2mg/day) for chemotherapy-induced peripheral neuropathy (CIPN). Results showed significant reduction in neuropathic pain NRS scores (−1.8 vs. −0.6 placebo) and improved sleep quality.
Massachusetts General Hospital / ALS Association
First RCT of CBD in ALS patients. Evaluates neuroprotective effects (ALSFRS-R progression), symptom management (pain, spasticity, sleep), and safety over 24 months. Motivated by preclinical CBN neuroprotection data.
University of Toronto / CAMH
RCT of low-dose oral THC (2.5–5mg) for chronic insomnia in adults aged 50+. Evaluates sleep onset latency, total sleep time, and next-day cognitive function using actigraphy and PSG at baseline and 4 weeks.
Stanford University School of Medicine
Pilot RCT of CBD (150–300mg/day) for social anxiety disorder in adolescents aged 13–17. First pediatric CBD anxiety trial. Evaluates LSAS-CA scores, fMRI amygdala reactivity, and safety over 8 weeks.
University College London / Moorfields Eye Hospital
Completed crossover RCT of sublingual CBD (40mg) and THC (5mg) for intraocular pressure in glaucoma. Results showed THC reduced IOP by 3.5 mmHg at 4 hours; CBD paradoxically increased IOP by 3.3 mmHg — a clinically important finding.
National Drug and Alcohol Research Centre, UNSW Sydney
Phase 3 RCT of nabiximols as substitution therapy for cannabis use disorder. Builds on Lintzeris et al. Phase 2 data. Evaluates cannabis abstinence, withdrawal severity, and quality of life over 12 weeks.
MD Anderson Cancer Center
RCT of CBD (300mg/day) for anxiety and sleep disturbance in cancer patients undergoing chemotherapy. Evaluates GAD-7, PSQI, and quality of life (FACT-G) over 12 weeks. Secondary endpoints include nausea and fatigue.
University of Michigan Medical School
First-in-human RCT of isolated β-caryophyllene (BCP) for inflammatory pain. Dose-escalation safety study with secondary endpoints of pain intensity (NRS) and inflammatory biomarkers. Motivated by strong CB2 agonist preclinical data.
Greenwich Biosciences / Jazz Pharmaceuticals
Long-term extension study of Epidiolex in tuberous sclerosis complex (TSC) patients who completed the pivotal Phase 3 GWPCARE6 trial. Evaluates 3-year seizure control, safety, and quality of life.
McGill University Health Centre
Pragmatic RCT comparing four cannabis formulations (high-CBD, balanced, high-THC, placebo) for fibromyalgia. Evaluates pain, fatigue, sleep, and cognitive function using patient-reported outcomes over 12 weeks.
VA San Diego Healthcare System
RCT of dronabinol (5–10mg at bedtime) for PTSD-related nightmares in combat veterans. Evaluates nightmare frequency (CAPS-5 item B2), sleep quality (PSQI), and overall PTSD severity over 7 weeks.
University of Edinburgh
First-in-human Phase 1 safety and pharmacokinetics study of CBG in healthy volunteers and IBD patients. Motivated by strong preclinical data showing CBG reduces colonic inflammation in murine colitis models.
University of California San Francisco
Completed comparative effectiveness RCT of inhaled cannabis vs. dronabinol vs. placebo for CINV. Results showed inhaled cannabis superior to dronabinol for acute nausea (NRS −2.1 vs. −1.4) with faster onset but more adverse effects.
University of Colorado Anschutz
RCT of CBD (300mg/day) for anxiety in Parkinson's disease. Evaluates HAM-A scores, motor function (UPDRS), sleep quality, and quality of life over 12 weeks. Secondary endpoint includes tremor severity.
Craig Hospital / University of Colorado
RCT of nabiximols for spasticity and neuropathic pain in spinal cord injury patients. Evaluates Modified Ashworth Scale, NRS pain, and quality of life over 6 weeks. Addresses a major unmet need in SCI rehabilitation.
University of California San Diego
RCT of CBD (400mg/day) for alcohol use disorder. Evaluates alcohol craving (PACS), drinks per drinking day, and relapse rates over 12 weeks. Motivated by preclinical data showing CBD reduces alcohol self-administration and relapse.
Angelman Syndrome Foundation / Boston Children's Hospital
Phase 3 RCT of Epidiolex for Angelman syndrome — evaluating both seizure frequency and behavioral outcomes (communication, sleep, anxiety) over 52 weeks. Angelman syndrome lacks FDA-approved treatments.
Trials are curated monthly from ClinicalTrials.gov and include studies registered in the US, EU, Canada, and Australia. We include Phase 1–4 interventional trials of cannabis-derived compounds (THC, CBD, CBG, CBN, nabiximols, dronabinol, nabilone, Epidiolex) and whole-plant cannabis for any medical condition.
NCT IDs link directly to the official ClinicalTrials.gov registry entry. Enrollment figures reflect planned enrollment at registration. Status is updated monthly — check ClinicalTrials.gov for real-time status. This tracker is for informational purposes only and does not constitute medical advice or an endorsement of any trial.
